Swiss stocks - Factors to watch on December 23

BERLIN/ZURICH, Dec 23 (Reuters) - The Swiss blue-chip SMI was seen opening 0.1% lower at 10,673 points on Monday, according to premarket indications from bank Julius Baer .

Here are some of the main factors that may affect Swiss stocks:


Credit Suisse said internal and external investigations found senior executive Peter Goerke was placed under observation on behalf of the bank in February, but there was no indication Chief Executive Tidjane Thiam was aware of the surveillance, echoing the findings of reviews conducted after former CS banker Iqbal Khan was tailed in September.

For more, click on


The Swiss drugmaker said it entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.

For more, click on


* DKSH said it signed an agreement to acquire specialty chemicals distributor Axieo, thereby expanding the geographical footprint of its Performance Materials Business Unit in the Pacific region.

* Schmolz+Bickenbach: NZZ reported that the company’s third-biggest shareholder, the founding families’ Schmolz+Bickenbach Beteiligungs GmbH, had taken legal action in front of the Swiss Federal Administrative Court against Swiss financial market watchdog FINMA’s decision to allow the two biggest shareholders’ to increase their stakes without submitting an offer for the remaining shares.



* No major Swiss economic data scheduled

Reporting by Zurich newsroom and Berlin Speed Desk